*Based on the average weight loss in three 68-week clinical trials of patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced- calorie diet and increased physical activity. See details. Results may vary based on starting weight and program adherence. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. Consult a healthcare professional before starting any weight loss program.
Zepbound is FDA-approved for type 2 diabetes treatment, but may be prescribed for weight loss. The trademarks, service marks, trade names (Wegovy®, Ozempic®), and products displayed on this Internet site are protected and belong to their respetive owners.
